Novartis agreed to pay 270 million euros ($364 million) upfront to license more than 10 projects in preclinical and early-stage development from Austrian biotech Intercell.
Eligible candidates include IC43 for prevention of hospital-acquired pseudomonas infections and IC47 for prevention of pneumonia infections, Novartis said.
The Swiss drugmaker will assume responsibility for the Phase III development, manufacturing and commercialization of any project.
Novartis has also secured opt-in rights to all future vaccine candidates discovered by Intercell during the long-term collaboration.
Source
No comments:
Post a Comment